UBS Group
PPCB

UBS Group’s Propanc Biopharma PPCB Stock Holding History

UBS Group’s Portfolio PPCB Stock Details PPCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.4K Buy
+7,305
New +$43.4K ﹤0.01% 7960

Other funds holding PPCB

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
SCA
Sassicaia Capital Advisers Jericho, New York $88.8M AUM 146.47% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

UBS Group's PPCB Position: Q1 2026 in Review

UBS Group opened a new position in Propanc Biopharma (PPCB) in Q1 2026: 7,305 shares worth $19.4K. The stake represents ﹤0.01% of the portfolio and ranks #7960 among its holdings.

6 funds tracked by Wall St. Rank hold PPCB as of Q1 2026.

  • UBS Group held 7,305 shares of Propanc Biopharma worth $19.4K as of Q1 2026.
  • Propanc Biopharma was a new UBS Group position in Q1 2026.
  • Propanc Biopharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7960 holding.
  • 6 funds tracked by Wall St. Rank held Propanc Biopharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.